Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | TP53 | P04637 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15965363 | 0.83 | TP53 (0.58) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL30955307 | 0.83 | TP53 (0.58) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL13692167 | 0.79 | TP53 (0.57) | MAPTTP53NPC1RAB9APKM | |
| SCHEMBL6267898 | 0.78 | MAPT (0.63) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL11729892 | 0.77 | MAPT (0.67) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL13401396 | 0.76 | MAPT (0.64) | MAPTPOLBNPC1RAB9ADHFR | |
| SCHEMBL5330904 | 0.76 | MAPT (0.61) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL1447326 | 0.75 | COMT (0.59) | MAPTTP53POLBNPC1RAB9A | |
| SCHEMBL5992360 | 0.75 | VCAM1 (0.60) | MAPTPOLBDHFR | |
| SCHEMBL12653007 | 0.74 | NPC1 (0.70) | MAPTTP53NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | MAPT 3729/4885TP53 209/4885POLB 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.